

# Evaluation of Lung Heterogeneity Corrections for Clinical Trials Using the RPC Lung Phantom

David Followill

P. Alvarez, A. Molineu, N. Hernandez, G. Ibbott

UT. M.D.Anderson Cancer Center

May 2007



# RPC History Lesson

Originated through agreement between AAPM  
and CRTS

Founded in 1968 to monitor institution  
participation in clinical trials (Bob Shalek)

Funded continuously by NCI as structure of  
cooperative group programs have changed



Now 39 years of experience of monitoring  
institutions and reporting findings to study  
groups and community

# Mission


- 1. Assure NCI and cooperative groups that institutions participating in clinical trials deliver prescribed doses that are comparable and consistent.**
- 2. Help institutions to make any corrections that might be needed.**
- 3. Report findings to the community.**

# Clinical Trial Participants

- Number of Active Institutions – 1,527
  - 2,989 megavoltage machines
  - 17,605 active megavoltage beams




# Only QA Office with relationships with all study groups




# RPC QA Activities

1. Remote TLD Reviews
2. Patient Dosimetry
3. On-site Reviews
4. Credentialing
  - Benchmark cases
  - Phantoms


# RPC Phantoms



4 prostate phantoms (IMRT)




9 thorax phantoms (SBRT)



25 H&N phantoms  
(IMRT)




SRS



2 liver phantoms  
(SBRT)

# Number of H&N Phantom Mailings





# Phantom Credentialing Process

**Call the RPC and get placed on the request list**

**Phantom is shipped**

**Phantom is imaged**

**Treatment plan developed by inst. per instructions**

**Treatment is delivered to the phantom**

**Phantom is returned to the RPC for data analysis**

**Treatment plan is submitted electronically to the ITC**

**The phantom is to be treated as if it were a patient.**




# Some institutions go overboard!!



**Some patients just want to better understand their treatment.**



# RPC Lung Phantom




# RPC Phantom

## Target dimension

Ovoid shape

3 cm diameter

5cm long



# RPC Phantom (cont.)


## Densities

Lung =  $0.33\text{g/cm}^3$


Heart, cord =  $1.1\text{ g/cm}^3$

Cord =  $1.31\text{ g/cm}^3$

Tumor =  $1.04\text{ g/cm}^3$



# RPC Phantom (cont.)



## Dosimeters

TLD and Gafchromic film

# Prescription

- Based on RTOG 0236 (SBRT Radioablation study)
  - Energies: 4 – 10 MV
  - $\geq 7$  non-opposing static fields or  $\geq 340^\circ$  arc rotation technique.
  - SBRT technique.
  - 20 Gy/fx to 95% of the PTV
  - Homogeneous planning and calculation of M.U.
  - Must submit heterogeneous plan based on homogeneous M.U. set



# Phantom Results

- A total of 30 irradiations were analyzed
- The 6 MV photon beam was used most often
- The TPSs used to plan the cases were:  
Pinnacle, BrainLab, XiO, Precise, Eclipse, Ergo and RenderPlan.
- Convolution Superposition algorithm was used most often.

# Phantom Results



TPS	Dose Calc. Algorithm	# irradiations	Center of Tumor TPS	
			$D_{\text{hetero}}/D_{\text{homo}}$	
Precise	Scatter Int. Clarkson	2	}	$1.19 \pm 2.6\%$
BrainLab	Clarkson & Pencil beam	5		$1.20 \pm 2.2\%$
Eclipse	Pencil Beam	5		$1.18 \pm 4.3\%$
Ergo	3D Convul. Pencil Beam	2		$1.19 \pm 0.1\%$
RenderPlan	Change in primary attenuation	1		1.20
Pinnacle	Adaptive convolve	10	}	$1.13 \pm 2.1\%$
XiO	Superposition/Convolution	5		$1.11 \pm 2.3\%$

**Clearly, there are two groupings**




# Phantom Results (cont'd)

TPS	Dose Calc. Algorithm	# irradiation	Center of Tumor
			Measured $D_{TLD}/D_{hetero}$
Precise	Scatter Int. Clarkson	2	$0.99 \pm 3.1\%$
BrainLab	Clarkson & Pencil beam	5	$0.96 \pm 2.4\%$
Eclipse	Pencil Beam	5	$0.96 \pm 1.8\%$
Ergo	3D Convul. Pencil Beam	2	$0.98 \pm 3.2\%$
RenderPlan	Change in primary attenuation	1	0.92
Pinnacle	Adaptive convolve	10	$0.99 \pm 2.1\%$
XiO	Superposition/Convolution	5	$0.96 \pm 2.0\%$

# Profile analysis




# Profile analysis



# PTV Periphery and Lung Points

**PTV = Tumor (CTV) + 0.5 cm in axial plane + 1 cm in longitudinal plane.**

**Lung constraint: points 2 cm from the PTV**



# Phantom Results (PTV Periphery)

TPS	Dose Calc. Algorithm	# irradiation	TPS $D_{\text{hetero}}/D_{\text{homo}}$ Axial plane
Precise	Scatter Int. Clarkson	2	1.20 ± 3.2%
BrainLab	Clarkson & Pencil beam	2	1.17 ± 1.6%
Eclipse	Pencil Beam	5	1.17 ± 4.3%
Ergo	3D Convul. Pencil Beam	2	1.18 ± 1.3%
Pinnacle	Adaptive convolve	10	1.06 ± 4.2%
XiO	Superposition/Convul.	3	1.08 ± 5.3%

**Two separate groupings again**

# Phantom Results (PTV Periphery) Measurements

TPS	Dose Calc. Algorithm	# irradiation	PTV Periphery measured $D_{TLD/film}/D_{hetero}$
Precise	Scatter Int. Clarkson	2	0.88
BrainLab	Clarkson & Pencil beam	2	0.84
Eclipse	Pencil Beam	5	0.87
Ergo	3D Convul. Pencil Beam	2	0.84
Pinnacle	Adaptive convolve	10	0.97
XiO	Superposition/Convul.	3	0.95

**Two separate groupings again**




# Phantom Results (Lung points)

TPS	Dose Calc. Algorithm	# irradiation	TPS $D_{\text{hetero}}/D_{\text{homo}}$ Axial plane
Precise	Scatter Int. Clarkson	2	1.19 ± 4.2%
BrainLab	Clarkson & Pencil beam	2	1.22 ± 5.5%
Eclipse	Pencil Beam	5	1.19 ± 8.3%
Ergo	3D Convul. Pencil Beam	2	1.20 ± 5.3%
Pinnacle	Adaptive convolve	10	1.12 ± 5.8%
XiO	Superposition/Convul.	3	1.12 ± 6.4%

**Two separate groupings again**

# Convolution R-L Profile


14



# Convolution Central 80 %

14

Comparison dose over 80% of PTV on RtLt profile




◆ RPC dose

■ Institution regression

# Convolution RPC/Inst.

14


RPC/Inst over 80% of PTV on Rt Lt profile



# Pencil-Beam profile

41


Right Left Profile  
Axial plane



# Pencil Beam - Central 80%


41

Comparison dose over 80% of PTV on RtLt profile



# Pencil Beam RPC/Inst

RPC/Inst over 80% of PTV on Rt Lt profile




# Summary of Systems Passing Existing Criteria

System/Algorithm	Percent of Points Within:		
	5%	7%	10%
Pencil Beam- Clarkson (n=9)	69 ±27%	83 ±14%	92 ±8%
Convolution- Superposition (n=11)	87 ±20%	95 ±13%	99 ±5%





**Pinnacle Calculation and Delivery  
Anterior-Posterior Profile**




PINNACLE

Pinnacle - axial #1 15 Jul 2005





**Pinnacle**

Corvus Calculation and Delivery  
Anterior-Posterior Profile



CORVUS



CORVUS

# Conclusions

- The average target TLD/Inst ratio is 0.97 (range 0.92 to 0.99). Good agreement for Convolution Superposition algorithms in the target.
- Large differences exist between the Convolution Superposition heterogeneity corrected dose calculations and other algorithms (ratios of 1.13 vs. 1.20).
- Heterogeneity corrected doses at the PTV periphery and lung points are higher than uncorrected doses.
- The Convolution Superposition algorithm calculations agree with the RPC measurements.
- New evaluation methods needed to assess each algorithm's accuracy

A photograph of a large, modern multi-story building at night. The building has a prominent central tower and several wings. The windows are illuminated from within, and some exterior lights are visible. In the foreground, there is a landscaped area with trees and low-lying plants, some of which are lit up. A road or driveway is visible in the lower right corner. The sky is a deep blue, suggesting dusk or dawn. The text "Thank you" is overlaid in the center of the image in a white, serif font.

Thank you